NCT00278174

Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer

A Phase II Trial of Interferon Alpha-1b (IFN Alpha-1b) in Patients With Metastatic Clear Cell Renal Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Case Comprehensive Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. PURPOSE: This phase II trial is studying how well interferon alfa works in treating patients with metastatic kidney cancer.

Detailed description

OBJECTIVES: Primary * Determine the objective response rate in patients with metastatic renal clear cell carcinoma treated with interferon alfa-1b. Secondary * Determine the toxicity of this drug in these patients. OUTLINE: This is an open-label study. Patients receive interferon alfa-1b subcutaneously daily. Treatment continues in the absence of unacceptable toxicity or disease progression. After completion of study treatment, patients are followed periodically. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Conditions

• Kidney Cancer

Interventions

Type	Name	Description
BIOLOGICAL	recombinant interferon alpha-1b

Timeline

• Start date: 2005-02-01
• Primary completion: 2007-04-01
• Completion: 2007-04-01
• First posted: 2006-01-18
• Last updated: 2011-05-04

Locations

1 site across 1 country: United States